Radiation Oncologist, Clinical Associate Professor, Division of Radiation Oncology
University of Calgary, Tom Baker Cancer Centre, Calgary, AB
Dr. Wu graduated from the University of British Columbia Faculty of Medicine in 1993. Upon completion of radiation oncology residency training there in 1998, he continued further training for 18 months as a clinical fellow in genitourinary and palliative oncology at the Princess Margaret Hospital. Thereafter, he became staff radiation oncologist at the Hamilton Regional Cancer Centre, where he worked two and a half years before relocating to Calgary in 2002. Since then, he has continued his clinical practice at the Tom Baker Cancer Centre. His clinical focus is palliative care in oncology, metastatic cancer to bone, metastatic cancer to brain, and prostate cancer.
He completed a MSc. in Clinical Epidemiology at the University of Toronto in 2007. Within the post-graduate, academic setting, he was exposed to a wide spectrum of research methods in health services, measurement and economics, as well as knowledge translation. His current research activities include outcomes evaluation, research methodology, biostatistical methods, and research ethics.
In the 10+ years as clinical radiation oncologist at the Tom Baker Cancer Centre, Dr. Wu participated in various national committees, such as the Royal College Examination Board in Radiation Oncology, the NCIC Clinical Trials Group Symptom Control Executive Committee, and the Canadian Association of Radiation Oncology scientific meeting committee. Since 2011, he has been serving as associate chair for Alberta Cancer Research ethics Committee (changed to HREBA Cancer Committee in 2014).
Relevant Publications
Chow E, van der Linden YM, Roos D, Hartsell WF, Hoskin P, Wu JSY, Brundage M, Abdenour N, Tissing-Tan CJA, Oei B, Babington S, Demas WF, Wilson CF, Meyer RM, Chen BE, Wong RKS. A Randomized Trial of Single and Multiple Fractions of Repeat Radiation for Painful Bone Metastases[NCIC CTG SC20 international intergroup study]. Lancet Oncol 2014;15(2), 164-171.
McIntyre JB, Wu JS, Craighead PS, Phan T, Kobel M, Lees-Miller SP, Ghatage P, Magliocco AM, Doll CM. PIK3CA Mutational Status and Overall Survival in Patients with Cervical Cancer Treated with Radical Chemoradiotherapy. Gynecol Oncol 2013 Mar;128(3):409-14.
Jung H, Sinnarajah A, Enns B, Voroney JP, Murray A, Pelletier G, Wu JS. Managing brain metastases patients with and without radiotherapy: Initial lessons from a team-based consult service through a multidisciplinary integrated palliative oncology clinic. Support Care Cancer 2013;21(12):3379-86.
Wu JS, Brasher P, El-Gayed A, Pervez N, Tai P, Robinson J, Skarsgard D, Joseph K, Sia M, Pearcey R. Phase II Study of Hypofractionated Image-Guided Radiotherapy for Localized Prostate Cancer: Outcomes of 55 Gy in 16 Fractions at 3.4 Gy per Fraction. Radiother Oncol 2012;103(2):210-6.
Wu JS. “Important Difference” for Interpreting Health-Related Quality of Life Outcome Measures: Important to Whom? (Editorial). Support Care Cancer 2012; 20(3):429-31.
Wu JS, Beaton D, Smith PM and Hagen NA. Pattern of Pain and Interface in Patients with Painful Bone Metastases: A Brief Pain Inventory Validation Study. Journal of Pain and Symptom Management, 39(2), 230-240. Feb 2010.